Tandem Diabetes Care, Inc. (TNDM) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-19

Business type: Asset play

How it makes money

It earns revenue by selling insulin pumps along with related single-use cartridges and infusion sets to people with insulin-dependent diabetes.

It generates nearly all of its sales from the sale of its insulin pumps and the related insulin cartridges and infusion sets. Its revenue depends heavily on ongoing purchases of these single-use supplies, which must be regularly replaced by the user to maintain insulin delivery.

Management considers its addressable market to include people living with type 1 diabetes, and starting in 2025, it began expanding its addressable market to include people living with type 2 diabetes who require intensive insulin therapy.

What protects it: the moat

It relies on proprietary automated insulin delivery algorithms and remote software update capabilities to maintain its competitive position in the pump market.

It develops automated insulin delivery systems using algorithms that integrate with continuous glucose monitoring sensors to automatically adjust insulin dosing. It also introduced remote software updates on its t:slim X2 pump in the United States, which management believes serves as a competitive advantage by delivering clinical and lifestyle enhancements to customers within their warranty cycle without requiring a new device.

What growth costs

It must continuously reinvest in research and development, manufacturing expansion, and commercial sales channels to support its ongoing business operations.

To implement its business strategy and pursue consistent profitability, it must fund ongoing research and development activities, create additional efficiencies in its manufacturing processes while adding capacity, and expand its sales channels, including the pharmacy channel in the United States. Management expects its expenses will continue to increase as it pursues these objectives and makes investments in the business.

What could damage it

Adverse changes in third-party reimbursement rates or policies could reduce product adoption and permanently impair its sales and operating results.

Because customers rely significantly on insurance coverage to purchase insulin pumps and consumable supplies, any unfavorable adjustments to reimbursement policies by third-party payors would directly restrict customer access and purchasing power. A reduction in coverage or less favorable reimbursement terms would diminish demand for its insulin delivery systems, directly undermining its revenue model.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Other companies in Medical Devices